After the vaccine triumphs of Pfizer/BioNTech and Moderna, a raft of startups is developing mRNA, circular RNA and self-amplifying RNA therapeutics.
A cadre of new startups are building next-generation RNA platform technologies designed to solve some of the unique challenges associated with using conventional mRNA tools as therapeutics.